Annual Drug Patent Expirations for XIGDUO+XR
Xigduo Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for XIGDUO XR.
This drug has two hundred and twenty-two patent family members in forty-six countries.
The generic ingredient in XIGDUO XR is dapagliflozin; metformin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the dapagliflozin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
